REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

GH Pulse

Growthintermediate
8
Peptides

2

Avg Daily mcg

0

Level

intermediate

Added

May 7, 2026

Overview

GH Pulse is an intermediate-level growth hormone optimization stack that combines two complementary peptides to restore youthful pulsatile GH secretion patterns. This clean, well-studied pairing is the gold standard introduction to serious GH peptide therapy, offering meaningful anabolic and recovery benefits without the complexity of advanced multi-compound protocols. Ipamorelin at 200mcg twice daily is a highly selective growth hormone secretagogue peptide (GHSP) that triggers acute GH release by binding ghrelin receptors (GHS-R) on pituitary somatotrophs. What distinguishes Ipamorelin from other secretagogues like GHRP-6 or GHRP-2 is its remarkable selectivity—it stimulates GH release without significantly elevating cortisol, prolactin, or appetite. This makes it the cleanest pulse trigger available. Twice-daily dosing creates a morning and evening GH spike that mimics the natural diurnal pattern seen in healthy young adults. CJC-1295 (no DAC) at 100mcg twice daily—also known as Modified GRF(1-29)—is a growth hormone releasing hormone analogue with a short half-life of approximately 30 minutes. Unlike the DAC version, this form creates acute GHRH signaling that amplifies each Ipamorelin-triggered pulse without creating sustained baseline elevation. The combination is synergistic: CJC-1295 primes the pituitary by providing the GHRH signal, while Ipamorelin simultaneously pulls the trigger via the ghrelin pathway. Research demonstrates that dual-pathway stimulation produces significantly greater GH output than either peptide alone. Protocol Notes: Both peptides should be administered together subcutaneously on an empty stomach—ideally upon waking (before breakfast) and before bed (at least 2 hours after last meal). Insulin and carbohydrates blunt GH release, so fasting windows around dosing are essential. This stack is well-suited for individuals seeking improved body composition, faster recovery from training, better sleep quality, and the general anti-aging benefits of optimized GH levels. It works particularly well for active adults over 30 noticing slower recovery. Standard cycles run 8-12 weeks, and users typically notice improved sleep quality and recovery within the first two weeks, with body composition changes becoming apparent by week 4-6.

Dosing Protocol

Ipamorelin

Twice per day· subcutaneous

200mcg

per dose

CJC-1295 (no DAC)

Twice per day· subcutaneous

100mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.